A powerful platform
FIT Biotech’s GTU® technology platform – which lies behind the FIT-06 immunomodulator used in the South African trials – is based around a special DNA plasmid capable of delivering selected genes to human cells.In addition to providing up to 100 times stronger and more persistent gene expression than standard plasmids, it offers versatility, cost-efficient production opportunities, together with freedom from the safety risks typical of viral vectors.
In addition to HIV, GTU® technology is also being used to develop a more efficient vaccine against tuberculosis than the existing BCG vaccine. Based on an immune response induced by genes of mycobacterial origin, a DNA vaccine using GTU® technology has the potential to elicit long-lasting, cell-mediated immunity.
Tuberculosis remains a major global health problem, as a third of the global population is estimated to be infected with mycobacterium and almost 2 million people die of tuberculosis annually.